surmount-1 tirzepatide trial obesity without diabetes

surmount-1 tirzepatide trial obesity without diabetes (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants SURMOUNT-1: Tirzepatide Drastically Reduces Weight

Name: surmount-1 tirzepatide trial obesity without diabetes (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants SURMOUNT-1: Tirzepatide Drastically Reduces Weight
Brand: gerloff.com
SKU: 8779396068
Price: 26.26 USD
Availability: InStock
Rating: 4.1836 (29 reviews)

SKU: 8779396068

4.2

USD26.26 USD61.26

Pay in 4 interest-free payments of $6.57 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 12 - Aug 17

Description

Cureus 17:e98275

It's an older GLP-1 option and may be suitable for some people

The products produced by our company are widely used in medicine, health care products, cosmetics, and other fields

While the results are highly encouraging, researchers caution that further evaluation and regulatory review are needed before retatrutide becomes widely available